| Literature DB >> 35595199 |
Sarin Kc1, Dian Faradiba1, Manit Sittimart2, Wanrudee Isaranuwatchai3, Aparna Ananthakrishnan1, Chayapat Rachatan1, Saudamini Dabak1, Asrul Akmal Shafie4, Anna Melissa Guerrero5, Auliya Suwantika6, Gagandeep Kang7, Jeonghoon Ahn8, Li Yang Hsu9, Mayfong Mayxay10, Natasha Howard11, Parinda Wattanasri12, Ryota Nakamura13, Tarun K George14, Yot Teerawattananon15.
Abstract
BACKGROUND: There are ongoing calls to harmonise and increase the use of COVID-19 vaccination certificates (CVCs) in Asia. Identifying groups in Asian societies who oppose CVCs and understanding their reasons can help formulate an effective CVCs policy in the region. However, no formal studies have explored this issue in Asia.Entities:
Keywords: COVID-19; Cross-border travel; Immunity certificate; Regional collaboration; Vaccination certificate; Vaccination passport
Mesh:
Substances:
Year: 2022 PMID: 35595199 PMCID: PMC9113761 DOI: 10.1016/j.tmaid.2022.102358
Source DB: PubMed Journal: Travel Med Infect Dis ISSN: 1477-8939 Impact factor: 20.441
Characteristics of study population and their response to adoption of CVCs.
| Variables | Regional Total, N (%) | Respond to adoption CVCs, N (%) | |
|---|---|---|---|
| N = 7714 (100) | Yes, 6717 (87) | No, 997 (13) | |
| Female | 3751 (49) | 3327 (89) | 424 (11) |
| Male | 3923 (51) | 3355 (86) | 568 (14) |
| Other | 40 (1) | 35 (88) | 5 (13) |
| No formal schooling | 8 (0) | 8 (100) | 0 (0) |
| High school or lower | 819 (11) | 660 (81) | 159 (19) |
| Undergraduate | 4404 (57) | 3841 (87) | 563 (13) |
| Postgraduate or higher | 2483 (32) | 2208 (89) | 275 (11) |
| India | 2002 (26) | 1627 (81) | 375 (19) |
| Indonesia | 396 (5) | 349 (88) | 47 (12) |
| Japan | 628 (8) | 500 (80) | 128 (20) |
| Laos | 199 (3) | 188 (94) | 11 (6) |
| Malaysia | 181 (2) | 168 (93) | 13 (7) |
| The Philippines | 2291 (30) | 2072 (90) | 219 (10) |
| Singapore | 163 (2) | 150 (92) | 13 (8) |
| South Korea | 520 (7) | 436 (84) | 84 (16) |
| Thailand | 1334 (17) | 1227 (92) | 107 (8) |
| Vaccinated | 6833 (89) | 6059 (89) | 774 (11) |
| Unvaccinated | 881 (11) | 658 (75) | 223 (25) |
| Vaccinated | 6833 (89) | 6059 (89) | 774 (11) |
| Awaiting my first dose | 414 (5) | 348 (84) | 66 (16) |
| Considering | 148 (2) | 86 (58) | 62 (42) |
| No intention | 66 (1) | 25 (38) | 41 (62) |
| Not available in my country | 29 (0) | 20 (69) | 9 (31) |
| Not in priority group | 136 (2) | 111 (82) | 25 (18) |
| Want a different brand | 88 (1) | 68 (77) | 20 (23) |
| Yes | 2085 (27) | 1898 (91) | 187 (9) |
| No | 5629 (73) | 4819 (86) | 810 (14) |
| Yes | 3853 (50) | 3607 (94) | 246 (6) |
| No | 3407 (44) | 2708 (79) | 699 (21) |
| Unemployed | 454 (6) | 402 (89) | 52 (11) |
| Yes | 6565 (85) | 5896 (90) | 669 (10) |
| No | 1149 (15) | 821 (71) | 328 (29) |
| Low level of trust | 1970 (26) | 1643 (83) | 327 (17) |
| Moderate level of trust | 2455 (32) | 2107 (86) | 348 (14) |
| High level of trust | 3289 (43) | 2967 (90) | 322 (10) |
| Agree | 4610 (60) | 4236 (92) | 374 (8) |
| Disagree | 1505 (20) | 1213 (81) | 292 (19) |
| Neutral | 1599 (21) | 1268 (79) | 331 (21) |
| Agree | 5364 (70) | 4950 (92) | 414 (8) |
| Disagree | 938 (12) | 664 (71) | 274 (29) |
| Neutral | 1412 (18) | 1103 (78) | 309 (22) |
| Agree | 5661 (73) | 5200 (92) | 461 (8) |
| Disagree | 791 (10) | 537 (68) | 254 (32) |
| Neutral | 1262 (16) | 980 (78) | 282 (22) |
| Agree | 5666 (73) | 5207 (92) | 459 (8) |
| Disagree | 709 (9) | 464 (65) | 245 (35) |
| Neutral | 1339 (17) | 1046 (78) | 293 (22) |
| Agree | 5753 (75) | 5275 (92) | 478 (8) |
| Disagree | 733 (10) | 478 (65) | 255 (35) |
| Neutral | 1228 (16) | 964 (79) | 264 (21) |
| Agree | 6159 (80) | 5605 (91) | 554 (9) |
| Disagree | 566 (7) | 364 (64) | 202 (36) |
| Neutral | 989 (13) | 748 (76) | 241 (24) |
Note: Column 2 provides a breakdown of total responses for all variables and their sub-categories, (%) are additive at column level. Columns 3, 4, & 5 provide response to the questions of whether respondents would adopt CVCs (Yes, No, and No response) and breakdown is given by individual variable, (%) is additive at row level.
Odds ratios, 95% confidence intervals, and p-values for responding “no” regarding adoption of CVCs from Model 1.
| Variables | Multiple logistic regression (Odds Ratio: OR) | ||
|---|---|---|---|
| OR for those who opposed the use of vaccination certificate (compared to those who accepted the use of vaccination certificate) | 95% Confidence Interval (CI) | P-value | |
| Unvaccinated | 2·01 | 1·65–2·46 | 0·000 |
| Low level of trust | 1·25 | 1·02 - 2·52 | 0·031 |
| Moderate level of trust | 1·21 | 1·00–1·45 | 0·048 |
| Do not have travel plan | 1·58 | 1·31–1·90 | 0·000 |
| Do not continue NPIs | 2·97 | 2·51–3·53 | 0·000 |
| Do not anticipate financial benefit | 2·35 | 1·98–2·78 | 0·000 |
| Unemployed | 1·40 | 0·99–1·98 | 0·058 |
| Disagree | 1·48 | 1·16–1·88 | 0·002 |
| Neutral | 1·47 | 1·19–1·82 | 0·000 |
| Disagree | 1·45 | 1·10–1·89 | 0·007 |
| Neutral | 1·49 | 1·20–1·84 | 0·000 |
| Disagree | 1·62 | 1·23–2·14 | 0·001 |
| Neutral | 1·50 | 1·19–1·90 | 0·001 |
| Disagree | 1·50 | 1·12–2·01 | 0·007 |
| Neutral | 1·17 | 0·93–1·47 | 0·177 |
| Disagree | 1·48 | 1·12–1·95 | 0·005 |
| Neutral | 1·08 | 0·85–1·37 | 0·542 |
| Disagree | 1·30 | 0·96–1·76 | 0·088 |
| Neutral | 1·14 | 0·89–1·46 | 0·298 |
| Female | 1·07 | 0·91–1·26 | 0·401 |
| Other | 0·92 | 0·29–1·93 | 0·890 |
| No formal schooling | 1·00 | ||
| Undergraduate | 0·71 | 0·57–0·90 | 0·004 |
| Postgraduate or higher | 0·63 | 0·49–0·82 | 0·000 |
| Indonesia | 0·51 | 0·35–0·75 | 0·001 |
| Japan | 0·61 | 0·46–0·82 | 0·001 |
| Laos | 0·37 | 0·20–0·71 | 0·003 |
| Malaysia | 0·48 | 0·26–0·87 | 0·016 |
| The Philippines | 0·47 | 0·38–0·59 | 0·000 |
| Singapore | 0·39 | 0·22–0·68 | 0·001 |
| South Korea | 0·97 | 0·74–1·28 | 0·838 |
| Thailand | 0·33 | 0·24–0·44 | 0·000 |
Odds ratios, 95% confidence intervals, and p-values for responding “no” regarding adoption of CVCs from Model 2.
| Variables | Multiple logistic regression (Odds Ratio: OR) | ||
|---|---|---|---|
| OR for those who opposed the use of vaccination certificate (compared to those who accepted the use of vaccination certificate) | 95% Confidence Interval (CI) | P-value | |
| Vaccination status | |||
| Registered and awaiting 1st dose | 1·49 | 1·10–2·02 | 0·011 |
| Still considering getting vaccinated | 3·16 | 2·19–4·55 | 0·000 |
| No intention of getting vaccinated | 4·25 | 2·24–8·08 | 0·000 |
| Vaccine not available in the country | 1·77 | 0·58–5·36 | 0·314 |
| Not in priority group | 1·55 | 0·95–2·52 | 0·077 |
| Want a different brand of vaccine | 1·96 | 1·10–3·51 | 0·023 |
| Low trust | 1·24 | 1·01 - 1·51 | 0·039 |
| Moderate trust | 1·21 | 1·01 - 1·46 | 0·044 |
| Do not have travel plan | 1·57 | 1·31–1·89 | 0·000 |
| Do not continue NPIs | 2·95 | 2·48–3·50 | 0·000 |
| Do not anticipate financial benefit | 2·33 | 1·96–2·76 | 0·000 |
| Unemployed | 1·42 | 1·01–2·00 | 0·046 |
| Disagree | 1·48 | 1·16–1·89 | 0·002 |
| Neutral | 1·47 | 1·19–1·82 | 0·000 |
| Disagree | 1·44 | 1·10–1·89 | 0·009 |
| Neutral | 1·49 | 1·20–1·84 | 0·000 |
| Disagree | 1·62 | 1·22–2·14 | 0·001 |
| Neutral | 1·50 | 1·19–1·90 | 0·001 |
| Disagree | 1·49 | 1·11–2·01 | 0·008 |
| Neutral | 1·18 | 0·93–1·48 | 0·167 |
| Disagree | 1·46 | 1·10–1·92 | 0·008 |
| Neutral | 1·07 | 0·84–1·36 | 0·594 |
| Disagree | 1·25 | 0·92–1·70 | 0·153 |
| Neutral | 1·13 | 0·88–1·45 | 0·328 |
| Female | 1·08 | 0·92–1·27 | 0·361 |
| Other | 0·95 | 0·30–2·99 | 0·931 |
| No formal schooling | 1·00 | ||
| Undergraduate | 0·71 | 0·56–0·89 | 0·003 |
| Postgraduate or higher | 0·63 | 0·49–0·82 | 0·000 |
| Indonesia | 0·50 | 0·34–0·74 | 0·000 |
| Japan | 0·62 | 0·46–0·83 | 0·002 |
| Laos | 0·37 | 0·19–0·70 | 0·003 |
| Malaysia | 0·47 | 0·26–0·87 | 0·016 |
| The Philippines | 0·48 | 0·38–0·60 | 0·000 |
| Singapore | 0·38 | 0·22–0·68 | 0·001 |
| South Korea | 0·96 | 0·72–1·27 | 0·757 |
| Thailand | 0·35 | 0·26–0·47 | 0·000 |